KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查 入排置信度 0.95

Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study.

John F R Robertson, Teimuraz Gogitidze, Zaza Katashvili, Juan Enrique Bargalló Rocha, Ekaterine Arkania, Iain Moppett, Kwok-Leung Cheung, Gia Nemsadze, Maxine Ajimi, Teresa Klinowska, Justin P O Lindemann, Alastair Mathewson, Christopher J Morrow, Myria Nikolaou, Maurizio Scaltriti, Andy Sykes, Giorgi Dzagnidze

J Clin Oncol 44(9) 750-761

PMID41628308
PMCIDPMC13001899
DOI10.1200/JCO-25-01548
发表日期2026-02-02
入排依据:The study is an oncology randomized trial with a drug intervention and original results, but it does not have a primary or key secondary time-to-event efficacy endpoint. Its primary endpoints are pharmacodynamic (ER expression, Ki67) from a presurgical window-of-opportunity design, not overall survival, progression-free survival, or other time-to-event outcomes. The phase is described as Phase III dose selection but the trial itself is a presurgical study, not a definitive Phase III efficacy trial.
入排复审未纳入:The study is an oncology randomized trial with a drug intervention and original results, but it does not have a primary or key secondary time-to-event efficacy endpoint. Its primary endpoints are pharmacodynamic (ER expression, Ki67) from a presurgical window-of-opportunity design, not overall survival, progression-free survival, or other time-to-event outcomes. The phase is described as Phase III dose selection but the trial itself is a presurgical study, not a definitive Phase III efficacy trial.
摘要

摘要

PURPOSE: SERENA-3 is a presurgical window-of-opportunity (WOO) trial exploring the pharmacodynamic effects of camizestrant in postmenopausal women with newly diagnosed estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative breast cancer. METHODS: This open-label, parallel-group trial randomly assigned 132 participants to receive camizestrant 75, 150, or 300 mg once daily for 5-7 days or 75 or 150 mg once daily for 12-15 days. The effects of camizestrant on ER expression, activity, and tumor proliferation were assessed in pre- and on-treatment tumor samples by immunohistochemical (IHC) analysis of ER, progesterone receptor (PgR), and Ki67. Exploratory analyses using transcriptomics and mass spectrometry were also performed. RESULTS: ER expression was reduced by approximately 65% for all camizestrant doses, regardless of treatment duration. Reduction in Ki67 expression was greater after 12-15 days of camizestrant treatment, compared with 5-7 days. Exploratory analyses including mass spectrometry and IHC image analysis aligned with IHC H-score, indicating equivalent, maximal effects of all tested doses of camizestrant on ER expression and activity and Ki67 expression. Of those participants receiving camizestrant 75 mg once daily, 90%-100% reported no treatment-emergent adverse events across all preferred terms; of those reported, all were Grade 1 except one participant with Grade 2 upper respiratory tract infection, not considered related to camizestrant. CONCLUSION: SERENA-3 demonstrates that camizestrant 75 mg once daily (Phase III dose) is well-tolerated and achieves maximal reduction in ER through known mechanisms, that is, antagonism and degradation, by 5-7 days, and proliferation suppression determined by Ki67 expression, by 12-15 days. These data support camizestrant 75 mg once daily as the preferred dose for ongoing clinical development and highlight the importance of presurgical WOO studies in guiding dose selection.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。